First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors-Reference-Cited by-同舟云学术

First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors

Published:2024-09-12 Issue:1 Volume:8 Page:
ISSN:2397-768X
Container-title:npj Precision Oncology
language:en
Short-container-title:npj Precis. Onc.

Author:

Zhang Jian,Du Yiqun,Meng Yanchun,Liu Xiaojun,Mu Yuxin,Liu Yunpeng,Shi Yehui,Wang Jufeng,Zang Aimin,Gu Shanzhi,Liu Tianshu,Zhou Huan,Guo Hongqian,Xiang Silong,Zhang Xialu,Wu Suqiong,Qi Huanhuan,Li Mengke,Hu Xichun^ORCID

Funder

CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41698-024-00687-7.pdf

Reference25 articles.

1. Costa, R. L. B., Brian, J. & Czerniecki, B. J. Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond. NPJ Breast Cancer 6, 10 (2020).

2. Ahn, S., Woo, J. W., Lee, K. & Park, S. Y. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J. Pathol. Transl. Med. 54, 34–44 (2020).

3. Fujimura, M. et al. HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab. Jpn J. Cancer Res. 93, 1250–1257 (2002).

4. Koopman, T. et al. HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison. J. Cancer Res Clin. Oncol. 141, 1343–1351 (2015).

5. Janjigian, Y. Y. et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann. Oncol. 23, 2656–2662 (2012).